Jitendra – Page 6 – Scilex Holding

18 Feb

Sorrento Posts Form 8937 to Supplement its Previously Issued
“FAQ” Regarding the Dividend of Scilex Holding Company Common
Stock (Nasdaq: SCLX, “Scilex”)

February 18, 2023
Posted by Jitendra

SAN DIEGO, February 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq:SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previouslyissued “Frequently Asked Questions” document under the...

15 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 15, 2023
Posted by Jitendra

15 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 15, 2023
Posted by Jitendra

15 Feb

SEC FIlings

Prospectus [Rule 424(b)(3)]

February 15, 2023
Posted by Jitendra

12 Feb

Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB^TM in the U.S. and Canada for the acute treatment of migraine

February 12, 2023
Posted by Jitendra

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The acute migraine drug market size...

06 Feb

SEC FIlings

Current report

February 6, 2023
Posted by Jitendra

04 Feb

Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

February 4, 2023
Posted by Jitendra

PALO ALTO, February 4, 2023 /Newswire/ -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused...

03 Feb

SEC FIlings